Sign up USA
Proactive Investors - Run By Investors For Investors

Pressure Biosciences' Barocycler instrument named finalist in 2017 R&D 100 awards

Finalists were chosen by an independent panel of more than 50 judges..
Pressure Biosciences'  Barocycler instrument named finalist in 2017 R&D 100 awards
This year's winners will be announced at a ceremony on November 17

Pressure Biosciences Inc (OTCQB: PBIO), the life sciences sector sample preparation firm, said its  next-generation PCT (pressure cycling technology) instrument - the Barocycler 2320EXTREME -  was selected as a finalist in the prestigious R&D 100 Awards for 2017.

Finalists were chosen by an independent panel of more than 50 judges, based on each product's impact potential, uniqueness, and technical capabilities, said the firm.

This year's winners will be announced at a ceremony on November 17 this year.

ProCan, a cancer research initiative in Australia and the first international collaborator of the US Cancer Moonshot program, purchased three of the products last year

Professor Phil Robinson, co-director, said: "We are collecting the whole proteome on 70,000 tumor samples from all classes where complete clinical outcome is known. The goal is to diagnose each individual patients' cancer to make more rapid and accurate predictions of the best cancer treatment to use -- or to avoid -- for that individual. This will also advance scientific discovery for new drug targets."

He added: "Due to its unique capabilities, the Barocycler 2320EXT has become a critical part of our program. It is the primary enabler of the high-throughput component of the project. Without this step, a project like ProCan simply could not be done."

Shares added 3.24% to US$4.14

View full PBIO profile View Profile

Pressure BioSciences Inc Timeline

Related Articles

couple looking at pregnancy test
November 13 2017
The proceeds from the fundraiser will be used to expand in the People's Republic and will invested in product development
picture of addict
November 15 2017
To build the UK's first £1bn, self-sustainable biotech is the aim for chief executive Clive Dix
numerous pills
March 23 2018
Genervon is on the lookout for pharma partners to help advance its GM6 drug, which takes aim at a range of deadly diseases hitting the central nervous system

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright ©, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use